Recurrent Osteosarcoma: Clinical Trials

8 trials for Recurrent Osteosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 8
Phase 23Completed 3

Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma
Phase 1 / Phase 2CompletedChildren's Oncology Group262018-01-312024-07-15
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)1402015-03-302023-10-17
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)782010-06-012018-08-15
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)242005-03-012013-06-05
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor
Phase 1CompletedNational Cancer Institute (NCI)702004-09-012013-06-04
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor
Phase 1CompletedNational Cancer Institute (NCI)952004-02-012013-06-05
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Phase 1CompletedNational Cancer Institute (NCI)302001-04-012013-07-02
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
tanespimycin, pharmacological study - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)601999-10-012013-02-07

Narrower conditions

Osteosarcoma (8)  ·  Neuroectodermal Tumors, Primitive, Peripheral (6)  ·  Neuroblastoma (5)  ·  Astrocytoma (3)  ·  Burkitt Lymphoma (3)  ·  Familial ependymoma (3)  ·  Medulloblastoma (3)  ·  Chondrosarcoma (2)  ·  Dendritic Cell Sarcoma, Interdigitating (2)  ·  Desmoplastic Small Round Cell Tumor (2)  ·  Hodgkin Disease (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Melanoma (2)  ·  Optic Nerve Glioma (2)

Broader conditions

Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Neoplasms, Bone Tissue (8)  ·  Neoplasms, Connective Tissue (8)  ·  Neoplasms, Connective and Soft Tissue (8)  ·  Neoplasms, Germ Cell and Embryonal (7)  ·  Neoplasms, Glandular and Epithelial (7)  ·  Neoplasms, Nerve Tissue (7)  ·  Neoplasms, Neuroepithelial (7)  ·  Neuroectodermal Tumors (7)  ·  Neuroectodermal Tumors, Primitive (7)  ·  Sarcoma (6)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)

Interventions

tanespimycin (2)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  CTLA-4 Antigen (1)  ·  Erlotinib Hydrochloride (1)  ·  HhAntag691 (1)  ·  Ipilimumab (1)  ·  Irinotecan (1)  ·  Nivolumab (1)  ·  Oxaliplatin (1)  ·  Temozolomide (1)  ·  alvocidib (1)  ·  pepinemab (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Children's Oncology Group (1)

Countries

United States (8)  ·  Canada (1)

Top investigators

Crystal L Mackall (1)  ·  Emily G Greengard (1)  ·  James Whitlock (1)  ·  Lisa McGregor (1)  ·  Mrinal Gounder (1)  ·  Ramesh Ramanathan (1)  ·  Regina Jakacki (1)  ·  Tanya Trippett (1)

Results publications

PMID 31401903, PMID 32192573, PMID 38520670

NIH funding

U01CA097452 (3), U01CA069856 (2), UM1CA097452 (2), N01CM62206 (1), P30CA008748 (1), U01CA099168 (1)